Brimonidine_tartrate: profile and news

Allergan Receives Positive Opinions for COMBIGAN(TM) from 21 ... Sep 28, 2005
...that it received positive opinions for COMBIGAN(TM), Allergan's ALPHAGAN(R)/timolol combination product for glaucoma (brimonidine tartrate/timolol ophthalmic ... - Business Wire (press release),

FDA Approvals: Aceon, 0.1% Alphagan P, Namenda Oral Solution Aug 25, 2005
...mortality or nonfatal myocardial infarction in patients with stable coronary artery disease; 0.1% formulation of brimonidine tartrate ophthalmic solution that ... - Medscape (subscription)

New Formulation of Allergan's ALPHAGAN(R) P Receives US FDA ... Aug 19, 2005
AGN) today announced it has received approval from the US Food and Drug Administration (FDA) to market ALPHAGAN(R) P (brimonidine tartrate ophthalmic solution ... - Business Wire (press release),

Stocks to Watch Northwest, Merck, HJ Heinz Aug 20, 2005
Administration. The new formulation is a 0.1% brimonidine tartrate ophthalmic solution as opposed to the original 0.2% formulation. ... - MarketWatch

Allergan Reports Second Quarter Operating Results and Increases ... Jul 27, 2005
The FDA issued an approvable letter for Alphagan(R) Z (brimonidine tartrate ophthalmic solution) for the lowering of intraocular pressure in patients with ... - Business Wire (press release)

Allergan Reports First Quarter Operating Results and Increases ... Apr 27, 2005
...approvable letter for Combigan(TM), Allergan's Alphagan(R)/ timolol combination product for the treatment of glaucoma (brimonidine tartrate/timolol ophthalmic ... - Business Wire

Alcon's First Quarter Earnings Rise 30.6 Percent on 11.1 Percent ... Apr 21, 2005
The company received a tentative approval from the FDA for brimonidine tartrate 0.15% with Polyquad(R) preservative for the treatment of glaucoma. ... - Business Wire,

Other information

Indication
For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Pharmacology
Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Mechanism Of Action
Brimonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Drug Category
Antihypertensive Agents; EENT Drugs; ATC:S01EA05

Brand Names/Synonyms
Alphagan; Alphagan P; Brimonidine; Brimonidine Tartrate; Bromoxidine; CHEMBANK1623

Dosage Forms
0.2% solution

Absorption
Minimal systemic absorption occurs after ocular insertion.

Interactions
-->Interactions for Brimonidine:

Although specific drug interaction studies have not been conducted with ALPHAGAN^® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN^® P in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after ALPHAGAN^® P administration are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

Chemical IUPAC Name
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

Chemical Formula
C11H10BrN5

Half Life
2 hours

Drug Type
Approved Drug

# Accession No
APRD00034

CAS Registry Number
59803-98-4